http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101744899-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2015-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101744899-B1 |
| titleOfInvention | Novel Antibody Binding to TFPI, and Composition Comprising the Same |
| abstract | The present invention relates to an antibody specifically binding to TFPI (Tissue factor pathway inhibitor), a nucleic acid encoding the antibody, a vector containing the nucleic acid, a host cell, a method for producing the antibody, The present invention relates to a therapeutic pharmaceutical composition. The antibody specifically binding to TFPI according to the present invention can activate the exogenous pathway of blood clotting by blocking TFPI, so that it is useful for the treatment of hemophilia patients with antibody and for the prevention of blood coagulation diseases of hemophilia-A or hemophilia-B patients Lt; / RTI > |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200034321-A |
| priorityDate | 2015-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 536.